ILMN vs. AVTR, PKI, A, MTD, WAT, TECH, CRL, BRKR, BIO, and PACB
Should you be buying Illumina stock or one of its competitors? The main competitors of Illumina include Avantor (AVTR), Revvity (PKI), Agilent Technologies (A), Mettler-Toledo International (MTD), Waters (WAT), Bio-Techne (TECH), Charles River Laboratories International (CRL), Bruker (BRKR), Bio-Rad Laboratories (BIO), and Pacific Biosciences of California (PACB).
Avantor (NYSE:AVTR) and Illumina (NASDAQ:ILMN) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, community ranking, profitability, dividends, valuation, analyst recommendations, earnings and media sentiment.
95.1% of Avantor shares are owned by institutional investors. Comparatively, 89.4% of Illumina shares are owned by institutional investors. 1.5% of Avantor shares are owned by company insiders. Comparatively, 0.2% of Illumina shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Avantor has higher revenue and earnings than Illumina. Illumina is trading at a lower price-to-earnings ratio than Avantor, indicating that it is currently the more affordable of the two stocks.
Illumina received 911 more outperform votes than Avantor when rated by MarketBeat users. Likewise, 65.71% of users gave Illumina an outperform vote while only 63.64% of users gave Avantor an outperform vote.
In the previous week, Illumina had 2 more articles in the media than Avantor. MarketBeat recorded 13 mentions for Illumina and 11 mentions for Avantor. Illumina's average media sentiment score of 1.04 beat Avantor's score of 0.68 indicating that Avantor is being referred to more favorably in the media.
Avantor has a net margin of 3.79% compared to Avantor's net margin of -28.71%. Illumina's return on equity of 13.01% beat Avantor's return on equity.
Avantor presently has a consensus price target of $26.71, suggesting a potential upside of 10.94%. Illumina has a consensus price target of $164.65, suggesting a potential upside of 57.89%. Given Avantor's higher possible upside, analysts plainly believe Illumina is more favorable than Avantor.
Avantor has a beta of 1.36, indicating that its share price is 36% more volatile than the S&P 500. Comparatively, Illumina has a beta of 1.2, indicating that its share price is 20% more volatile than the S&P 500.
Summary
Avantor beats Illumina on 13 of the 18 factors compared between the two stocks.
Get Illumina News Delivered to You Automatically
Sign up to receive the latest news and ratings for ILMN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ILMN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Illumina Competitors List
Related Companies and Tools
